10X Genomics Hits New 52-Week High of $40.05, Up 76% Year-Over-Year

10X Genomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 40.05 on July 1, 2026. This achievement marks a remarkable performance over the past year, with the stock appreciating by 76.06%, significantly outpacing the S&P 500's gain of 20.74% during the same period. The company's market capitalization stands at USD 2,489 million, reflecting its position within the small-cap category. Despite being a loss-making entity, 10X Genomics has shown resilience in the market, as indicated by its price-to-book ratio of 3.13. The company currently does not offer a dividend, and its debt-to-equity ratio is reported at -0.64, suggesting a unique financial structure. The stock's previous 52-week low was recorded at USD 11.16, highlighting the substantial growth it has experienced. As 10X Genomics continues to navigate the competitive landscape of the biotechnology industry, this new high underscores its evolving market dynamics and performance metrics.